granlen-the reliability 201605

63
A Reliable and Innovative Partner to Speed up Your Success The Reliable Leading Nucleoside Pioneer!

Upload: harry-an

Post on 10-Feb-2017

190 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Granlen-The Reliability 201605

A Reliable and Innovative Partner to Speed up Your Success

The Reliable Leading Nucleoside Pioneer!

Page 2: Granlen-The Reliability 201605

Outline

Overview ∙ Experience ∙ Services ∙ Granlen

Page 3: Granlen-The Reliability 201605

Corporate Locations

美国加州圣地亚哥–太平洋彼岸的“人间天堂”,最适于居住的城市San Diego, CA

- The Paradise on Earth;the

most livable city

中国郑州 - 重要交通枢纽,商贸中心,国家园林城市Zhengzhou, China

- The key transportation and

business central garden city

Page 4: Granlen-The Reliability 201605

About Granlen

• Provides reliable chemistry related services for the biotech, pharmaceutical, diagnostic, cosmeceutical, and related industries with:

– A broad spectrum of chemistry

– A wide range of drug discovery services

– An integrated drug development process to IND

Page 5: Granlen-The Reliability 201605

The Granlen Difference

Satisfy your needs Speed your success

Committed to Total Quality Excellence

Page 6: Granlen-The Reliability 201605

Granlen’s Strengths

Synthetic Organic Chemistry

Medicinal Chemistry

Combinatorial Technologies

Drug discovery and development to IND

Immunogens and bioreagents

6

Page 7: Granlen-The Reliability 201605

Synthetic Organic Chemistry

Heterocyclic and macrocyclic derivatives

Natural products and derivatives

Peptides, carbohydrates, glycopeptides

Process development and large scale synthesis – mg to multi-kg scale

Page 8: Granlen-The Reliability 201605

Medicinal Chemistry

Hit-to-lead

Lead Optimization– Natural products

– SAR studies

– Liability removal

– Automation for expansion

Integrated preclinical discovery services

Page 9: Granlen-The Reliability 201605

Medicinal Chemistry

Target Expertise

KinasesMicrotubulesPolymerases

ProteasomeReverse TranscriptaseRNA

GPCRsOther key enzymes

Therapeutic Experience

Oncology

Infectious AntiviralAntibacterialAnti-TB

Metabolic disordersObesityDyslipidemiaDiabetes

Page 10: Granlen-The Reliability 201605

Our History of Success

OncologyMicrotubule polymerization inhibitor (Phase II)

Kinase inhibitor (Phase II)

Proteasome Inhibitor (Preclinical)

Medicinal Chemistry and Drug Development

AntiviralAn HBV drug (Phase III)

An HIV drug (Phase II)

An HCV drug (Phase II)

An HIV drug (Phase I)

An HCV candidate (IND)

Page 11: Granlen-The Reliability 201605

CombiChem and Automation for Medicinal Chemistry

Solution-phase chemistry - parallel or indexedSolid-phase methodologies

• Method development

• Focused libraries and parallel synthesis

• Supporting material modification

• Solid-phase extraction technology

• Library enumeration and tracking

Expertise in nucleoside libraries andfocused heterocyclic libraries

Page 12: Granlen-The Reliability 201605

Carbohydrate Derivatives

S

OO

HO

S

OBzBzO

BzO

OAc

S

OHOH

HOO

OO

HO

OO

OOHO

O

O

OBnBnO

BnO

O

O

OAcF

p-TolOOAc O

OAcN3

p-TolOOAc

O

OHBzO

BzOOBz

O

OAc

BzO OAcO

OAcO

BzO OAcO

OAcBzO

BzO OAc

H3C

O

OAc

F

BzO OAc

H3C

O

OAcCH3

BzO OAc

O

OBzBzO

BzOOAc

CH3

O

OAcCl2BnO

Cl2BnOOAc

O

O

OBnO

BnO

IO

O

OBnO

BnO

HO

O

OAc

HO

BzO OAc

O

OAcp-TolO

OAc

Page 13: Granlen-The Reliability 201605

Representative Pyrimidine Nucleosides

NO

OHH, F, N3, NH2, CH3,

MeO

HO

N

OH, NH2

O

R

O

H, F, N3, NH2, CH3

HO N

OH

O

OH

OF, N3, NH2,

HO

HO N

N

OH, NH2

O

O

H, F, N3, NH2, CH3

HO

OH

N

N

O

O

H, F, N3, NH2, CH3

HO

OH

N O

O2N

O

H, F, N3, NH2, CH3,

MeO,

HO

OH

N

N

O

NH2

R

H, OH

N

OH, NH2

ONO

OHHO

HO

N3, CH3, CN

R

NO

OHHO

HO

N

OH, NH2

O

R

CH3

NO

OH, N3, NH2, F, Cl, OMe

HO

HO

N

OH, NH2

O

R

O

HO

HO N

N

O

F

H, OH, NH2

R

O

F,HO

HO N

NH

O

S

OR

R

NS

OHHO

HO

N

OH, NH2

O

R

O

H, OH, OMe, F

OH

N

N

O

O

R

O

HO,F,N3

HO

H,OH,OR,F, N3

N

NH

S

O

R

NO

HO

N

OH, NH2

O

R

Page 14: Granlen-The Reliability 201605

Representative Purine Nucleosides

N

N

N

H, OH, NH2, Cl, OMe, NHR, R

NO

OH, N3, NH2, OMe, OR, CH2CH2OMe, O-ethynyl

HO

HO

O

HO

HO

F, H

N

Y

N

N

H, NH2, Cl, OH, OMe

H, NH2, Cl, OH, OMe

NH

N

N

O

NO

OH, ORHO

HOH, NH2, I, SH, SR, CH3, NHR

R

N

NN

N+

O

HO

HO

NH2

NH, NHR

OH

R

N

OHO

R

N

NN

N

OH, NH2

H, NH2

H, NH2

H, OH

N

N

N

H, OH, NH2, Cl, OMe, NHR, R, Ar, Het

NO

OHH, F, N3, NH2, CH3, MeO

HO H, NH2

NH

NN

N

S

O

OH, HH, F, N3, CH3

HOH, NH2

O

H, F, N3, NH2, CH3, MeO,

HO

OH

N

N

NH

N

NH2

O

H, FOF, N3,

NH2, HO

HO

H, OH

N

N

N

H, OH, NH2, Cl

N H, NH2

Page 15: Granlen-The Reliability 201605

3’-Fluoro-3’-deoxy Pyrimidine/Pyridinone Nucleosides

Page 16: Granlen-The Reliability 201605

3’-Fluoro-3’-deoxy Purine Nucleosides

Page 17: Granlen-The Reliability 201605

2’-Fluoro-2’-deoxy Pyrimidine Arabinonucleosides

Page 18: Granlen-The Reliability 201605

2’-Fluoro-2’-deoxy Purine Arabinonucleosides

Page 19: Granlen-The Reliability 201605

Azido-Nucleosides

Page 20: Granlen-The Reliability 201605

Amino-Nucleosides

Page 21: Granlen-The Reliability 201605

Isocytidines and Isoguanosines

Page 22: Granlen-The Reliability 201605

Thio-Nucleosides

Page 23: Granlen-The Reliability 201605

Xylofuranose-nucleosides

Page 24: Granlen-The Reliability 201605

2’,3’-Dideoxy Substituted Nucleosides

Page 25: Granlen-The Reliability 201605

2’,3’-Dideoxy / didehydro-Nucleosides

Page 26: Granlen-The Reliability 201605

3’-Methyl-3’-deoxy and 3’-Deoxy Nucleosides

Page 27: Granlen-The Reliability 201605

Pyrimidinone and Pyridinone Nucleosides

(3-Deaza-/4-deoxy Us)

Page 28: Granlen-The Reliability 201605

6-Deamino and 6-Methylpurine Nucleosides

Page 29: Granlen-The Reliability 201605

2-Subsituted Purine Nucleosides

Page 30: Granlen-The Reliability 201605

5’-Modified Nucleosides

Page 31: Granlen-The Reliability 201605

Nucleosides Having One Reactive Group on Sugar

Page 32: Granlen-The Reliability 201605

Morpholino-Nucleosides

Page 33: Granlen-The Reliability 201605

PNA Monomers

Page 34: Granlen-The Reliability 201605

Drugs and Inhibitors

Page 35: Granlen-The Reliability 201605

Nucleotides, Amidites and Phosphonates

O

O

NH2

O

O-

N

NN

NO

NH2

OO

O

P-O O

N

N

O

P O-O

NH

R

NVOCO

H

R'

ON

OHR

N

NH2

O

HOOH

ON

N

N

NH

O

O

OMeO

P O

P O-S

O

NH2

R = H, OMe

dinucleotides

N

OH, NH2

ONO

ROH

PHO O

OH

PO

N

NC

NH

O

ONO

RO

PRO O

OR RR

O

R

N

N

Z

NH

O

RPO

PO

P-O -O

OO

-O

O

O-

X

XR

phosphonamiditeH-phosphonate

N

NN

N

O

O

DMTrO

NHBz

OPO

N

NC

NH

NN

N

O

O

DMTrO

O

NHBui

OP

O

N

NC OCH3

N R

N

N

N

NH2

O

R OR

P O

RO

HO

XX

triphosphonatesphosphonates

phosphoramidites

phosphonate amidites

PO

O-

N

N

ONO

R

ODMTr

H3C

H

PO

N

NC

NH

O

ONO

R

ODMTr

H3CNCH3

+HNEt3

Page 36: Granlen-The Reliability 201605

Representative Nucleoside Phosphoramidites

Page 37: Granlen-The Reliability 201605

Nucleoside Phosphoramidites

NH

NN

N

O

O

O

O

NH

O

O

DMTr

PO

N

NC

NH

NN

N

O

O

O

O

NH

O

O

DMTr

PO

N

NC OCH3

Page 38: Granlen-The Reliability 201605

Nucleoside Triphosphates (NTPs)

LC (TIC)

LC (UV)

1) P(O)(OMe)3 proton sponge 2) POCl3 3) Pyrophosphate

1) ion exchange column2) reverse phase column

3) LyopholizationN

O

OCH3OH

OP

O

O

O-

P

O

O-

OP

O

O-

-O

NH

O

O

n Et3NH+

NO

OCH3OH

HO

NH

O

O

H3C H3C

Page 39: Granlen-The Reliability 201605

39

Other Products with Different Applications

N

SN

N+N

Cl-

HO OH

Dipropofol/ drug standard

Catalyst

HON

OH

OH

OH

OH CH3

O

Mega 8 /Bio-reagent

N NCOOR

N

ROOC

COOR

COORROOC

H2N

MRI Contrasting Agents

DDAIP-HCl (Formulation)

O

NH+

O

Cl-

Phenothiazine

O

O

O

O

R

R

R

R

RuN+

N+

X

X

OH

O

O

O-

Complex /bio-reagent

SO3H

SO3H

N

N N

N

O

OHOH

ONH

NC

ClCl

NH2

HSP30 inhibitorFlavor Additive

O O

Page 40: Granlen-The Reliability 201605

Purine Derivatives

Page 41: Granlen-The Reliability 201605

Pyrimidines, Pyrazines and Pyradazines

Page 42: Granlen-The Reliability 201605

Other Building Blocks

Page 43: Granlen-The Reliability 201605

Natural Products and Derivatives

N N

H2N

CH3

O

OCH3

O

HN

O

HO

HN

HN

CH3

N

H2N

NH

NH2

OO

NH

HO

S

O

O

S

NNH

O

R2

O

OHO

HO

HO

OH R1

OH

OH

NH

N

H

H

H

HH

H

NH2

H

HCH3

R1 = OCONH2, OH; R2 = SMe, +SMe2

7 Bleomycins including: Bleomycin A2, Bleomycin

demethyl A2, and Decarbamoyl Bleomycin Demethyl A2

>48 steps each for the total synthesis

Bleomycin Antitumor Antibiotics

R3

H

O

X

OR

H

OR

H

O

OR

Oridonin

5'-Alkylresorcinols isolated from Hakea trifurcatea DNA cleaving agents

l m n

HO

OH

OH

OH

Page 44: Granlen-The Reliability 201605

Our Specialties

Carbohydrates, nucleosides/tides, & libraries

Phosphoramidites, phosphates, triphosphates,

C-phosphonates

Natural product total synthesis

Heterocycles, macrocycles, super-chelating and MRI contrast agents

Immunogens/antigens and bio-reagents

Prodrug and conjugation technologies

Page 45: Granlen-The Reliability 201605

Chemistry Services

Hit to lead & lead optimization

Screening & focused libraries

Custom Synthesis

Chemistry &Drug Discovery

PreclinicalDevelopment

ClinicalDevelopment

Page 46: Granlen-The Reliability 201605

Hit and Lead Optimization

Hit re-synthesis for activity confirmation

Lead selection and optimization for SAR studies

Design & synthesis of analogs for lead improvement

Optimize potency, selectivity, specificity, and safety

Improve PK, PD, and druggability

Enhancement of IP coverage

Page 47: Granlen-The Reliability 201605

Screening and Focused Libraries

Screening library enhancement

Drug-like or Lead-like (Ro5)

Toxicophore filtration

Focused libraries around specified targets

Structure/Ligand-based design

Optimization by virtual screening

10-50 mg per sample with >90% purity

Page 48: Granlen-The Reliability 201605

Custom Synthesis

Products, intermediates, scaffolds, building

blocks, monomers, raw materials

Reference and competitor compounds

Drug standards, metabolites and impurities

Immunogens/antigens, bio-reagents

Radiolabeling method development

Page 49: Granlen-The Reliability 201605

IND-Enabling Preclinical Services

Process development research & LSS

Analytical method development and stability studies

Regulatory and documentation

Chemistry &Drug Discovery

PreclinicalDevelopment

ClinicalDevelopment

Page 50: Granlen-The Reliability 201605

Process Development & LSS

Route scouting to Route finalization

Reaction condition / process optimization

Efficient processes for multi-kilo scales

Scalable and transferable

processes

Kilo to ton scale manufacture

Page 51: Granlen-The Reliability 201605

Analytical Services

Develop and validate analytical methods

Establish drug criteria for drug substances and pharmaceutical products

Drug stability studies:

– Freeze-thaw

– Forced degradation

– Accelerated and long-term stability

Page 52: Granlen-The Reliability 201605

Intellectual Property ProtectionIntellectual Property Protection

Highest Priority

Isolated facility to ensure IP protection

Strict documentation procedures

Professional management team focused on IP protection

Intellectual property belongs to the client

Page 53: Granlen-The Reliability 201605

Our ClientsGlobal clients in US, Canada, Singapore, Japan, India,

Europe, and China

Custom synthesis, drug discovery, analytical method,

process development, LS synthesis, pre-clinic CMC etc

Services include Focused libraries, hit design and synthesis, lead optimization for SAR

Synthesis of nucleosides, phosphoramidites, triphosphates, heterocyclic and macrocyclic derivatives, drug standards, metabolites, impurities, etc

Conjugation, asymmetric compounds, formulation products, organic materials, dyes, bio-reagents, etc

Pre-clinical development, methods and pharmaceutical

53

Page 54: Granlen-The Reliability 201605

Example 1 - Drug Discovery Project

Participated in the project plan from very early stage

Designed potential hit/lead structures to be selected

Designed routes and worked out synthesis

Bi-weekly report and adjust direction as needed

Submitted high quality samples for biological tests

and write-up document

Secure confidentiality and client owns the IP

Luckily, a great lead was discovered

Page 55: Granlen-The Reliability 201605

Example 2 – IND Enabling Drug Development

Require: pre-clinical CMC and pharmaceutical for IND

Explored possible routes and finalized the best one

Fine-tuned reaction conditions and processes (batches)

Allow cost reduction of 80% for production

3 kg high quality product met drug requirements and used for clinical studies

Developed anal method, established drug criteria, QC

Provided all documents to support IND application

Page 56: Granlen-The Reliability 201605

Example 3 –New Phosphonate Amidite

Required: 20 g of new phosphonate phosphoramidite

Designed reasonable and doable route

Worked out the key steps and accomplished smoothly

Delivered high-quality product and write-up document

with all data in ~60% expected time frame

“Harry, That’s great and fast! I had a failed delivery

before on the same compound”, the client said after

the project was completed

Page 57: Granlen-The Reliability 201605

Example 4 – Halo-Nucleoside

Required: 50 g scale synthesis (for big pharma; failed

by other vendors before)

Designed the un-reported new route, and it was

agreed by client

Explored and synthesized halo-sugar

Synthesized and delivered final product in high

quality and timely fashion

We are the only group who can make this type of

nucleosides in sizable scale (a Large CRO failed on the

same compound)

Page 58: Granlen-The Reliability 201605

Here is what one of our clients said:

Haoyun,

Very impressive! No one can beat you on this area. Please send me the invoice for this PO.

Best Regards,John

Page 59: Granlen-The Reliability 201605

Operation & Facilities

Headquartered in San Diego, CA (Sign CDA in US)

Operation in Zhengzhou, China

The transportation and business central garden city

Hydrogenator, high-pressure reactors, shakers, large

evaporator, and 100 L reactors for large scale synthesis

Anal/semi-preparative HPLCs, medium pressure LC,

lyophilizer, LC-MS, NMR, HRMS, FT-IR, UV-Vis, DSC/TG,

X-ray, polarimeter, stability test chambers, etc

Page 60: Granlen-The Reliability 201605

60

The quality of our equipment is nothing

when compared to the quality of our people!

Corners of Granlen

Page 61: Granlen-The Reliability 201605

One View in Zhengzhou

Page 62: Granlen-The Reliability 201605

Summary

Highly experienced management

Unique specialties and highly skilled teams

Quality > Reliability > Costs

No challenge to great or small (Serve/Help)

Timely communication for high efficiency

Continuously improving infrastructure

We deliver regardless what it takes

Page 63: Granlen-The Reliability 201605

We Work Harder!

[email protected]

Skype: haoyun.an

QQ: 1015260133

1-760-846-6460 (US)

011-86-158-38132863 (China)

011-86-371-86026726 (China)

The Reliable Leading Nucleoside Pioneer!